Epicardial Technologies Inc.
This article was originally published in Start Up
Executive Summary
Epicardial Technologies Inc. is developing a technology platform designed to enable physicians to more easily perform percutaneous, catheter-based ablation of common heart rhythm abnormalities, from the inside or the outside surface of the heart, while protecting the structures surrounding the heart from serious damage or injury. The company says its products will enable electrophysiologists to do what only surgeons can currently accomplish-effectively ablate aberrant electrical signals on the heart's outside surface-without opening the chest.
You may also be interested in...
Start-Up Previews (02/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Antibody Platforms," features profiles of arGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology. Plus these Start-Ups Across Health Care: BioMarker Strategies, BMEYE, Clear Catheter Systesm, Epicardial Technologies and Optibrium.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.